The Role of Master Protocols in Pediatric Drug Development

Area of Science:

• Clinical trial design
• Pediatric drug development
• Regulatory science

Background:

• Master protocols are advanced clinical trial designs with limited application in pediatric drug development, particularly outside of oncology.
• Pediatric drug development often faces challenges due to small patient populations, especially for rare and ultra-rare diseases.
• Regulatory requirements from agencies like the FDA and EMA necessitate pediatric studies, often based on adult data and extrapolation.

Purpose of the Study:

• To explore the application of master protocols in pediatric drug development programs required by regulatory agencies.
• To address the challenges of conducting clinical trials in small pediatric populations.
• To demonstrate the potential of collaborative platform trials in pediatric rare diseases.

Main Methods:

• Review of master protocol applications in pediatric drug development.
• Description of a collaborative, cross-company pediatric platform trial in pediatric Crohn's disease.
• Focus on aspects like shared infrastructure, regulatory submissions, control group selection, and pediatric extrapolation.
• Utilizing innovative Bayesian analysis for the platform trial.

Main Results:

• Master protocols can streamline clinical development and potentially reduce sample sizes or improve enrollment in pediatric studies.
• Collaborative efforts between companies can facilitate the design and execution of complex pediatric platform trials.
• The use of master protocols can expedite pediatric marketing approvals, leading to faster patient access.

Conclusions:

• Master protocols represent a significant opportunity to enhance pediatric drug development efficiency and timeliness.
• Cross-company collaborations on platform trials can overcome challenges in rare pediatric diseases.
• Implementing master protocols can accelerate the availability of safe and effective medications for children.